GANTANOL-DS
LOE ApproachingNDAORALTABLET
Approved
Aug 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTANOL-DS is an oral tablet antibiotic approved by Roche in 1965. The generic name and mechanism of action are not available in current data, but this product represents a legacy small-molecule therapeutic. Patient population and indications require updated clinical documentation.
LOE Approaching
With LOE approaching and minimal linked job activity, the brand team is likely in sustainment or transition mode with constrained growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GANTANOL-DS currently shows zero linked job opportunities, reflecting its mature lifecycle stage and approaching loss of exclusivity. Career growth on this product is limited; professionals should expect sustainment responsibilities rather than launch or expansion initiatives.
Brand ManagerField Sales Representative
Worked on GANTANOL-DS at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.